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Background:  The  management  of post-meniscectomy  pain  is  poorly  standardised.  Allogeneic  transplan-
tation  may  be appropriate  in some  patients  after  total meniscectomy.  After  partial  meniscectomy,  the
synthetic  meniscal  substitute  Actiﬁt® may  constitute  a valid  option  if the  knee  is  stable  or stabilised  and
aligned  or  re-aligned.  The  interconnected  pore  structure  of  Actiﬁt® promotes  tissue  regeneration  from
the meniscal  wall.  Arthroscopy  is  used  to  position  the  implant,  which  is  then  sutured  to  the  remaining
native  meniscus  using  horizontal  stitches  and to the meniscal  wall  using  vertical  stitches.  However,  a
burdensome  programme  of rigorous  rehabilitation  is required  after  Actiﬁt® implantation.
Hypothesis:  We hypothesised  that  implantation  of a  meniscal  substitute  effectively  alleviated  pain  with-
out  adversely  affecting  the  knee.
Objectives:  To  assess  the intra-articular  behaviour  of Actiﬁt® and the  outcomes  of  Actiﬁt® implantation
in  a  prospective  case-series  of  patients  monitored  using  arthroscopy,  pathology,  and  imaging  studies,  as
well as the Lysholm  score  to  assess  clinical  beneﬁts  on  daily  activities.
Materials  and methods:  Between  October  2009  and  April  2012,  18  patients  underwent  Actiﬁt® implanta-
tion  at  the  military  hospital  in  Brest,  France.  All procedures  were  performed  by the  same  surgeon,  who
had extensive  experience  with  meniscal  suturing.  There  were  13 males  and  5  females  aged  20  to  46  years.
The  medial  meniscus  was  involved  in  13 patients  and  the  lateral  meniscus  in 5  patients.  Actiﬁt® implan-
tation  was  used  alone  in 6 patients  and in  combination  with  anterior  cruciate  ligament  reconstruction
and/or  realignment  osteotomy  in  12  patients.  All  patients  were  followed-up  for  at least  2 years.
Results:  The  mean  Lysholm  score  after  1  year  was 92%, indicating  excellent  outcomes.  Magnetic  res-
onance  imaging  showed  no  damage  to  the  implant  or degeneration  of  the  neighbouring  cartilage.
Histological  examination  of  meniscal  substitute  biopsies  taken  1 year  after  implantation  showed  poly-
mer  ingrowth  by  normal  chondrocytes  and  ﬁbrochondrocytes.  The clinical  and  radiographic  outcomes
compared  favourably  with  those  seen  after  isolated  procedures  on  bone  or ligaments.
®Discussion:  Actiﬁt has no deleterious  effects  on patients.  The  implant  induces  and  promotes  menis-
cal  regeneration.  Actiﬁt® constitutes  a major  addition  to our  therapeutic  armamentarium.  We  provide
convincing  evidence  that  meniscal  reconstruction  can  be highly  beneﬁcial  in  decreasing  the  risk  of
progression  to knee  osteoarthritis.
Level  of evidence:  IV.
© 2014  Elsevier  Masson  SAS.  All  rights  reserved.. IntroductionAs military surgeons, we provide care to many young athletic
ndividuals who engage in activities that cause trauma to the joints.
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877-0568/© 2014 Elsevier Masson SAS. All rights reserved.This young population is at high risk for knee disorders, most
notably damage to the menisci [1]. We  encounter difﬁcult chal-
lenges raised by individuals younger than 40 years of age with knee
pain and meniscal lesions that inevitably result in knee osteoarthri-
tis if left untreated [2].
Several treatment options are available for these patients.
Meniscal repair by suturing is feasible in some cases [3]. Another
option consists of replacing the meniscus with either allogeneic
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•Fig. 1. Actiﬁt®: appearance of the implant to the naked eye (left) and high
ransplants or synthetic substitutes [4]. Finally, a scaffold impreg-
ated with growth factors can be implanted to induce meniscal
issue regeneration [5].
Until now, we had no effective treatment options for young
atients with knee pain after partial meniscectomy. Our team at
he Brest military hospital therefore decided to use the meniscal
ubstitute Actiﬁt® in this situation [6].
The objective of this study was to assess the intra-articular
ehaviour of Actiﬁt® and the clinical beneﬁts of Actiﬁt® implanta-
ion on the everyday life of these patients with chronic knee pain.
o this end, we performed a prospective cohort study.
. Material and methods
.1. Material
Actiﬁt® [6] is a synthetic polymer composed of poly-ε-
aprolactone acid and polyurethane. The matrix (Fig. 1) is
haracterized by a highly interconnected pore structure that
ncourages tissue regeneration from the meniscal wall [7]. The
rimary stability of the substitute facilitates implantation and
roduces favourable mechanical sensations.
From the meniscal wall, whose preservation is mandatory [8]
Fig. 2), blood vessels develop and grow into the honeycomb struc-
ure of the implant (Fig. 3). The result is regeneration of the meniscal
issue. Over the years, once regeneration is complete, breakdown
f the replacement matrix occurs.
Although some degree of dexterity is required, meniscal trans-
lantation is within the reach of any surgeon who is experienced in
rthroscopic procedures. Different kits are available for the medial
nd lateral menisci. A special ruler is always provided to allow mea-
urement of the defect produced by the meniscectomy. A meniscal
uture kit is required to stitch the implant to the meniscal wall
nd residual meniscus, and the all-inside technique is the most
ppropriate.The technique itself involves the following steps:
preparation of the meniscectomy region and abrasion of the
meniscal wall (Fig. 4);
Fig. 3. Diagrams illustrating the principle of tissFig. 2. Arthroscopic appearance of a well-vascularised meniscal wall.
• measurement of the meniscal defect (Fig. 5);
• cutting of the implant to match the size of the defect (Fig. 6);
• positioning of the implant in the knee;
• suturing of the implant to the meniscal wall and residual menis-
cus (Fig. 7).
2.2. Methods
Replacement of part of a damaged meniscus can be considered
only if the criteria below are met:
• knee pain with a visual analogue scale (VAS) score >6/10 every
day for more than 6 months;
• stable knee or knee scheduled for stabilisation;
• normally aligned knee or knee scheduled for realignment;
• intact meniscal wall;
• intact meniscal anchors.In addition, the cartilage damage in the involved tibio-femoral
compartment should not exceed grade II in the Kellgren–Lawrence
radiological classiﬁcation.
ue ingrowth into the synthetic substitute.
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3. Resultsig. 5. Arthroscopic view showing use of the ruler to measure the meniscal defect.
This set of criteria served as inclusion criteria for our study.
ll procedures were performed at the Clermont-Tonnerre Military
eaching Hospital by a single surgeon who had extensive experi-
nce with arthroscopic surgery and meniscal suturing.
After the procedure, all patients were managed at our rehabil-
tation department, where they followed the 24-week stepwise
ehabilitation programme recommended by the manufacturer of
ctiﬁt®. Weight bearing on the operated lower limb was  com-
letely eliminated for 1 month then, resumed gradually until full
eight bearing was reached after 9 weeks.
Fig. 7. Arthroscopic views showing implant positioFig. 6. The meniscal substitute is cut to size. The cut is bevelled to improve contact
with the residual meniscus.
The patients were re-evaluated by the surgeon after 3, 6, and
12 months, then once a year. Follow-up was  at least 2 years in all
study patients. The Lysholm score was  determined at each visit.
Magnetic resonance imaging (MRI) was  performed after 1 year and
whenever a further surgical procedure was required, most notably
in the event of material removal, in which case arthroscopy with a
biopsy of the implant was performed.Between October 2009 and April 2012, 18 patients were
prospectively included into the study, 13 males and 5 females aged
ning and suturing to the residual meniscus.















Fig. 9. Changes in the Lysholm score in our 18 patients from baseline to last follow-
up.
F
cig. 8. Distribution of procedures used in combination with implantation of a syn-
hetic meniscal substitute in 18 patients.
0 to 46 years. Among them, 13 had damage to the medial meniscus
nd 5 to the lateral meniscus. Actiﬁt® implantation was performed
lone in 6 patients (Fig. 8). The remaining 12 patients also under-
ent anterior cruciate ligament reconstruction and/or realignment
steotomy.
The intra- and postoperative complications consisted of resid-
al knee pain due to median saphenous nerve injury in 1 patient
nd quadriceps weakness due to a femoral nerve conduction block
elated to the regional anaesthesia in another.
Follow-up was  at least 2 years in all 18 patients. No patients were
ost to follow-up. The Lysholm score changes showed a marked clin-
cal improvement as early as 6 months after the procedure. After
 year, the mean Lysholm score was 92%, indicating an excellent
esult (Fig. 9). After 2 years, all 18 patients had returned to their
Fig. 10. Magnetic resonance imaging of the knee, sagittal and coronal views: t
ig. 11. Microphotographs in 300 dpi resolution obtained with × 400 magniﬁcation of s
ontaining normal chondrocytes and ﬁbrochondrocytes.usual everyday activities and 9 had resumed their sporting activi-
ties at the same level as before the procedure.
MRI  was performed 1 year after surgery in all 18 patients. The
implant was seen as a structure of intermediate signal intensity
that had the shape of the meniscal triangle (Fig. 10). No cases
of implant separation or meniscal degeneration were recorded.
Meniscal extrusion was  visualised in 1 patient but had no clinical
impact.
An arthroscopic biopsy of the implant was  performed 1 year
after surgery in 3 patients. The histological study (Fig. 11) showed
that the polymer was  colonised by normal chondrocytes and ﬁbro-
chondrocytes.
he medial meniscal implant generates a signal of intermediate intensity.




















































polyurethane scaffold: two-years safety and clinical outcomes. Am J Sports
Med  2012;40:844–53 [Epub Feb 9].
[14] Commission nationale d’évaluation des dispositifs médicaux et des technolo-C. Baynat et al. / Orthopaedics & Traumatol
. Discussion
As military surgeons, we provide care to young athletic individ-
als in whom one goal is to maintain operational ability for as long
s possible. These speciﬁc characteristics raise challenges in the
anagement of post-meniscectomy knee pain. To meet the expec-
ations of the members of the armed services, we  investigated the
otential beneﬁts of meniscal substitute therapy. The support of our
ospital pharmacy was  crucial in allowing this endeavour, as the
ost of each Actiﬁt® implant is about 2000 D. Our primary objective
as to demonstrate that Actiﬁt® implantation had no deleterious
ffects on the patients. The clinical and radiological data collected
fter 4 years of experience with Actiﬁt® are extremely encouraging
nd compare favourably with the outcomes obtained after bone or
igament surgery alone.
The ﬁrst meniscal substitute was the collagen meniscal implant
CMI) composed of bovine collagen. In 98 patients who under-
ent medial meniscus reconstruction with the CMI, Beauﬁls et al.
howed that 87% of patients had normal knees after 1 year, with a
ean Lysholm score of 97% [9]. MRI  was performed after 1 year in
ll 98 patients and showed no adverse effects on the neighbouring
artilage or evidence of early degeneration. In April 2009, Makrides
t al. reported the outcomes of 6 patients managed with the CMI  to
econstruct the lateral (n = 4) or medial (n = 2) meniscus [10]. After
 months, all 6 patients were free of pain and the mean Lysholm
core was 96%.
Despite these promising results, the same teams, who  by then
ad acquired considerable experience with meniscal transplan-
ation, were drawn to evaluate the synthetic polymer substitute
ctiﬁt®. In a study involving routine arthroscopy and implant
iopsy after 1 year, Verdonk and Forsyth [11] showed ingrowth of
ative meniscal tissue into the implant, which consistently pro-
uced viable tissue with no evidence of necrosis. In April 2011, the
ame Belgian team reported 3-month data on tissue ingrowth into
ctiﬁt® implants in 52 patients evaluated using dynamic contrast-
nhanced MRI  [12]. Tissue ingrowth was documented in 81.4% of
atients.
Our prospective study has an obvious source of bias in that 12 of
he 18 patients underwent another procedure in addition to Actiﬁt®
mplantation. Thus, although clinical beneﬁts were recorded, we
annot determine with certainty that they were directly related
o Actiﬁt® implantation. Nevertheless, our optimism regarding the
eneﬁcial effects of Actiﬁt® is supported by the results of earlier
tudies. The Actiﬁt® Study Group reported a multicenter case-series
tudy of 52 patients managed using Actiﬁt® implantation alone
13]. Signiﬁcant improvements were recorded for pain and function
IKDC score, KOOS, and Lysholm score). In addition, the condition
f the cartilage (ICRS grade) remained unchanged or improved in
2.5% of patients.. Conclusion
Actiﬁt® induces and supports meniscal regeneration. This
mplant constitutes a major addition to our therapeuticurgery & Research 100S (2014) S385–S389 S389
armamentarium. We  are conﬁdent that meniscal reconstruc-
tion can prove beneﬁcial in decreasing the risk of progression to
osteoarthritis.
Unfortunately, the French National Authority for Health (HAS)
recently ruled [14] that the beneﬁts from Actiﬁt® were not suf-
ﬁcient to warrant reimbursement of the implant by the French
statutory healthcare system. Nevertheless, we  will continue to
use this synthetic implant while striving to diversify our practice
by also using meniscal substitutes derived from native menis-
cal tissue, such as the T-meniscus®, with the goal of providing
optimal care to our young patients with symptomatic meniscal
lesions.
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